Loading
PATINA showed that adding the CDK4/6 inhibitor palbociclib to maintenance antibody and hormone treatment kept breast cancers that are both hormone receptor- and HER2-positive under control for markedly longer.
About half of HER2-positive breast cancers also express hormone receptors, and the two signalling routes cross-talk. PATINA randomised 518 patients with hormone receptor-positive, HER2-positive metastatic breast cancer who had completed four to eight cycles of induction chemotherapy with trastuzumab and pertuzumab without progression to maintenance anti-HER2 therapy plus endocrine therapy with or without palbociclib. The primary endpoint was investigator-assessed progression-free survival.
Palbociclib lengthened progression-free survival substantially with manageable toxicity, mainly neutropenia. The result, reported in December 2024, established CDK4/6 inhibition as part of maintenance for this double-positive group.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
518 enrolled.
Median follow-up 53.5 months
SourcePredominantly neutropenia
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (investigator-assessed)primary | Palbociclib + anti-HER2 + endocrine maintenance | 261 | 44.3 months | 0.75 (0.59 to 0.96) | 0.02 (two-sided) | link |
| Anti-HER2 + endocrine maintenance | 257 | 29.1 months | ||||
| Grade 3 adverse events | Palbociclib + anti-HER2 + endocrine maintenance | 261 | 79.7% | - | - | link |
| Anti-HER2 + endocrine maintenance | 257 | 30.6% | ||||
| Grade 4 adverse events | Palbociclib + anti-HER2 + endocrine maintenance | 261 | 10% | - | - | link |
| Anti-HER2 + endocrine maintenance | 257 | 3.6% |
Shares Palbociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen), Breast cancer (all types) and the tag subtype-trials.
Shares Trastuzumab, HER2-positive breast cancer, Breast cancer (all types) and the tag subtype-trials.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer and the tag subtype-trials.
Shares Letrozole (and other aromatase inhibitors), Breast cancer (all types) and the tag subtype-trials.
Shares HER2-positive breast cancer, Breast cancer (all types) and the tag subtype-trials.
Shares Pertuzumab, Trastuzumab and the tag subtype-trials.
Shares HER2-positive breast cancer, Breast cancer (all types) and the tag subtype-trials.
Shares Breast cancer (all types), HR-positive / HER2-negative breast cancer and the tag subtype-trials.